Pancreatic cancer

A novel mRNA vaccine effectively triggered an antitumor immune response in a mouse model of pancreatic cancer, even completely eliminating the cancer in a…

The U.S. Food and Drug Administration (FDA) has approved an oral drug for adults with pancreatic adenocarcinoma, the most common form of pancreatic cancer,…

Silexion Therapeutics has launched a Phase 2/3 clinical trial testing its experimental therapy SIL204 in combination with standard-of-care chemotherapy in people with pancreatic…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly’s experimental medication olomorasib as a potential treatment for previously…

An anticancer vaccine targeting a common genetic driver of pancreatic cancer was shown to be safe in an early clinical trial, with the results…

A $16 million research initiative is bringing together scientists from six U.S. cancer centers to build on recent breakthroughs in targeted therapies and develop longer-lasting…

Dosing has begun in a global clinical trial testing Revolution Medicines‘ RAS(ON) inhibitor candidate zoldonrasib as a first-line treatment for advanced pancreatic ductal carcinoma…

Treatment with Revolution Medicines‘ oral daraxonrasib more than doubled overall survival versus standard chemotherapy among adults with previously treated metastatic pancreatic cancer in…

Ideaya Biosciences and Roche announced a collaboration to test two experimental treatments for pancreatic cancer in combination. The companies will test Ideaya’s…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental delivery method for the chemotherapy oxaliplatin as a potential treatment…